What are the clinical features, severity spectrum, and management options for beta thalassemia?

Beta Thalassemia: Clinical Features, Severity Spectrum, and Management

Clinical Spectrum and Pathophysiology

Beta thalassemia encompasses three distinct clinical phenotypes of increasing severity: the carrier state (thalassemia minor), thalassemia intermedia, and thalassemia major—a severe transfusion-dependent anemia that without treatment causes death in early childhood. 1

The disease results from reduced (β+) or absent (β0) synthesis of beta-globin chains, leading to:

• Globin chain imbalance with excess alpha-globin chains precipitating in red blood cell precursors 2
• Ineffective erythropoiesis from both mechanical and oxidative damage 1
• Chronic hemolytic anemia 3
• Progressive iron overload from increased intestinal absorption and transfusions 1

Severity Modifiers

Disease severity depends on several genetic factors 1:

• Degree of α-globin chain excess (primary determinant)
• Inheritance of mild/silent β-thalassemia mutations
• Coinheritance of α-thalassemia alleles
• Increased γ-globin chain production (fetal hemoglobin)

Management Algorithm

Thalassemia Major (Transfusion-Dependent)

For patients with thalassemia major, initiate regular blood transfusions combined with iron chelation therapy as the foundation of management, with hematopoietic stem cell transplantation (HSCT) pursued as soon as possible in eligible patients to prevent iron-related complications. 4

Standard Medical Management

• Regular blood transfusions to maintain adequate hemoglobin and suppress ineffective erythropoiesis 5
• Iron chelation therapy (oral or parenteral) to prevent cardiac disease, endocrinopathies, and osteoporosis 5
• Cardiac monitoring using advanced cardiac MRI for early detection of myocardial iron deposition 5

Curative Therapy: HSCT

HSCT should be performed in the first years of life before iron-related complications develop, particularly in patients under 14 years of age with an HLA-matched sibling donor. 4

Key outcomes from modern HSCT 4:

• Overall survival: 91% and disease-free survival: 83% in recent large series
• Transplant-related mortality: ≤5% in young, low-risk children with matched sibling donors
• Age threshold of 14 years is critical: patients <14 years achieve 96% disease-free survival vs. 74% in older patients
• Patient status at transplantation is the most critical predictor of outcome—perform HSCT early to avoid transfusion-associated complications

Risk stratification uses three factors 4:

• Age at transplantation
• Organ dysfunction from iron overload
• Hepatomegaly and liver fibrosis

Emerging Therapies

Gene therapy represents a potentially curative one-time treatment, with FDA-approved ZYNTEGLO now available, though limited by cost (USD 2.8 million per patient). 6

Novel therapeutic approaches under investigation 3, 2:

• Pharmacologic enhancers of effective erythropoiesis
• Modulators targeting ineffective erythropoiesis
• Stem cell gene therapy

Thalassemia Intermedia

Patients require 1:

• Monitoring for complications without regular transfusions
• Selective transfusions during periods of increased stress
• Iron chelation if transfusion burden increases
• Screening for endocrinopathies starting at age 11 years 7

Thalassemia Minor (Carrier State)

• Asymptomatic carriers require genetic counseling 8
• Prenatal diagnosis available for at-risk couples 8

Monitoring for Complications

Endocrine Complications

Regular endocrine screening should begin before age 10 years in transfusion-dependent patients and from age 11 years onward in non-transfusion-dependent patients. 7

Common endocrinopathies in transfusion-dependent thalassemia major 7:

• Hypogonadism and delayed puberty
• Growth retardation
• Osteopenia/osteoporosis
• Hypothyroidism
• Diabetes mellitus
• Hypoparathyroidism
• Adrenal insufficiency
• Reproductive dysfunction

Cardiac Complications

Cardiac disease from iron deposition is the leading cause of death in developed countries, typically occurring from the third decade due to noncompliance with deferoxamine; in underdeveloped countries, cardiac death begins at age 12 years due to unavailability of chelation therapy. 5

Critical Pitfalls to Avoid

• Delaying HSCT beyond age 14 years significantly worsens outcomes—transplant as early as possible in eligible patients 4
• Inadequate iron chelation leads to irreversible cardiac damage, endocrinopathies, and premature death 5
• Missing rare thalassemia variants with conventional screening—consider advanced sequencing methods when phenotype-genotype mismatch exists 9
• Failing to screen for endocrinopathies before age 10 in transfusion-dependent patients misses the window for intervention 7
• Assuming non-transfusion-dependent patients are complication-free—they also develop endocrinopathies and require monitoring from age 11 7

Global Health Considerations

In low-income countries where optimal transfusion and chelation therapy are unavailable, HSCT remains the only viable curative approach, though access is severely limited. 4

With modern standardized transfusion and iron chelation therapy, patients can now survive into the fourth or fifth decade of life, transforming thalassemia major from a rapidly fatal childhood disease into a chronic condition 4. However, adherence to chelation therapy can prevent or even reverse endocrine complications 7.